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Background: Multiple sclerosis (MS) is a chronic progressive neurological disease and the majority of patients will
experience some degree of impaired mobility. We evaluated the prevalence, severity and burden of walking and
mobility problems (WMPs) in 5 European countries.
Methods: This was a cross-sectional, patient record-based study involving 340 neurologists who completed detailed
patient record forms (PRF) for patients (>18 years) attending their clinic with MS. Patients were also invited to
complete a questionnaire (PSC). Information collected included demographics, disease characteristics, work
productivity, quality of life (QoL; EuroQol-5D and Hamburg Quality of Life Questionnaire Multiple Sclerosis
[HAQUAMS]) and mobility (subjective patient-reported and objectively measured using the timed 25 foot walk test
[T25FW]). Relationships between WMPs and disease and other characteristics were examined using Chi square tests.
Analysis of variance was used to examine relationships between mobility measures and work productivity.
Results: Records were available for 3572 patients of whom 2171 also completed a PSC. WMPs were regarded as the most
bothersome symptom by almost half of patients who responded (43%; 291/683). There was a clear, independent and
strong directional relationship between severity of WMPs (subjective and objective) and healthcare resource utilisation.
Patients with longer T25FW times (indicating greater walking impairment) were significantly more likely to require
additional caregiver support (p < 0.0001), visit a variety of healthcare professionals including their primary care physicians
(p = 0.0044) and require more long-term non-disease modifying drugs
(p = 0.0001). A similar pattern was observed when subjective reporting of the severity of WMPs was considered. Work
productivity was also markedly impacted by the presence of WMPs with fewer patients working full time and a reduction
in weekly working hours as T25FW times and the subjective severity of WMPs increased.
Conclusions: In Europe, WMPs in MS represent a considerable personal and social burden both financially and in terms of
quality of life. Interventions to improve mobility could have significant benefits for patients and society as a whole.
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Multiple sclerosis (MS) is a chronic inflammatory-
demyelinating disease leading to progressive neurological
impairment and an array of debilitating symptoms [1,2].
MS affects around 2.5 million people worldwide, is more
common among women than men, and is usually diag-
nosed in adults approximately 30 years old World Health
Organization. Multiple Sclerosis International Federation.
Atlas: Multiple Sclerosis Resources in the World [3]). MS
is often accompanied by functional impairment due to a* Correspondence: james.pike@adelphigroup.com
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reproduction in any medium, provided the orrange of symptoms that contribute to mobility problems
including impaired walking ability, loss of arm function,
loss of balance, weakness, and muscle spasticity [2,4]. It
has been estimated that within 10–15 years of an initial
diagnosis of MS, approximately 80% of patients will ex-
perience some degree of impaired mobility [4].
Loss of mobility has been shown to impact markedly
on employment status, with increasing levels of impair-
ment (as measured using the Expanded Disability Status
Scale [EDSS; [5]]) associated with increasing levels of un-
employment [6]. Consequently, while the life expectancy
of patients diagnosed with MS might be similar to that
of the healthy general population [7], their ability to sup-
port themselves and any dependents, both financiallytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toms of MS. Indeed, loss of productivity either through
inability to work, working fewer hours or as a result of
having to switch to a less demanding occupation has
been estimated to be the single largest contributory fac-
tor to the societal burden of the disease [8].
Mobility problems in patients with MS are also
strongly related to reduced health-related quality of life
(HRQoL) and can profoundly affect the ability of indivi-
duals to live independently [6,7,9–14]. Patients with MS
can incur considerable costs associated with the
provision of mobility aids, home/workplace adaptations,
and the requirement for both formal and informal care
in order to achieve activities of daily living (ADLs;
[7,8,11,14]). The personal physical, emotional and finan-
cial burden on informal, unpaid caregivers can also be
considerable [15–19]. Caregivers may experience detri-
mental effects on their own quality of life, particularly
when caring for patients with more severe symptoms or
with an unstable disease course [15].
Evaluating the severity and impact of mobility pro-
blems in MS is essential for the systematic evaluation of
the associated disease burden and in the assessment of
the effect of interventions to relieve or improve the
symptoms of the disease. The evaluation of mobility pro-
blems has often relied on subjective reporting by patients
or the physician-recorded EDSS which, in its upper end,
relies on walking ability (maximum distance) as a
measure of mobility problems. Objective, formalized,
physician-administered tools for the evaluation and as-
sessment of walking ability in MS are available and in-
clude the timed 25-foot walk (T25FW; [20]). Worsening
T25FW is associated with worsening neurological func-
tioning and disability [21–23], and has been indirectly
correlated to increased care burden and decreased prod-
uctivity and quality of life [24].
We report here the prevalence, severity and economic
burden of walking and mobility problems (WMPs)
among patients with MS in 5 European countries (97%
of whom were of working age (≤65)). We also relate both
self-reported and objectively measured WMPs (using the
T25FW) to important aspects of the burden of MS in-
cluding ability to self-care, healthcare resource
utilization, and ability to work, providing a comprehen-




The MS Disease Specific Programme (DSP®) is a cross-
sectional real world survey of doctors and their consulting
patients conducted in five EU countries between Septem-
ber and November 2009. A total of 340 neurologists in
France, Germany, Italy, Spain, and the UK participated inthe programme. All patients with MS, as diagnosed by
their physician, were eligible for inclusion in the survey. Its
real world design ensured collection only of information
available to the physician/patient at the time of consult-
ation. Therefore, no tests or investigations were required
or conducted for a patient to be included in the study. The
full methodology for this survey has been outlined previ-
ously [25]. It was performed according to the European
Pharmaceutical Market Research Association (EphMRA)
Guidelines, and in full accord with HIPAA standards.
While ethical approval was not required, each patient pro-
vided written consent for anonymous and aggregated
reporting of research findings as required by the
guidelines.Physician-reported data
During the study period, each participating neurologist
completed a detailed patient record form (PRF) for the
next 10–12 consecutive patients with MS over the age of
18. Physicians provided information from patient records
on healthcare resource utilization including hospitaliza-
tions, ER visits, physician consultations, other healthcare
professional consultations, and support therapy. Physi-
cians were also asked to provide T25FW data where
available but were asked not to conduct the test specific-
ally for the purposes of this study. T25FW data were
categorized into 3 ambulation classes relating to comple-
tion of the test in <11 seconds, between 11 and 21 sec-
onds, and times in excess of 21 seconds. Given the
cross-sectional nature of the data recorded in the
Adelphi MS DSP and that worsening walking ability
(higher T25FW times) have previously been shown to be
associated with worsening neurological functioning and
disability [21–23], categorising of the T25FW data in this
way allowed the evaluation of the impact of higher
T25FW times on the variables included in this report.Patient-reported data
Participating neurologists were also asked to invite
patients for whom they completed a PRF to complete a
patient self-completion questionnaire (PSC) about their
disease, diagnosis, health-related quality of life (HRQoL;
as assessed using the EuroQol-5D [EQ-5D] and
HAQUAMS), and symptoms including the presence and
severity of WMPs. Patients were asked to indicate
whether, in their own opinion, their WMPs were mild,
moderate, or severe, and to specify their requirement for
additional caregiver support (professional or non-profes-
sional), home or work modifications, and mobility aids.
Patients were also asked about their employment status
and the impact of their MS on their ability to work in-
cluding time lost to work in the previous 12 months due
to their MS.
Table 1 Demographics and disease characteristics




Mean age, years 40.6
Mean body mass index, kg/m2 23.9
Mean number of years since diagnosis of MS 4.6
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confidentiality and to avoid bias at the data collection
and analysis phases. The study protocol followed ethical
procedures including informed consent of all patients for
anonymous and aggregated reporting of research find-
ings based on the questionnaires employed. Patients
were instructed by the physician to complete the PSC in-
dependently and return it in a sealed envelope, thus en-
suring that the physician could not see the responses.
Matching the physician and patient responses via patient
and physician study numbers allowed the PSC data to be
linked with comparable data recorded on the physician-
completed PRF. The analyses conducted for the purposes
of this paper investigated data from the matched PRF
and PSC records.
Statistical analysis
Chi-squared tests with posthoc Bonferroni-adjusted Chi-
squared tests or Fisher’s Exact tests were used to assess
the relationship between the T25FW and physician- and
patient-reported disease characteristics and healthcare
resource utilization. Analysis of variance (ANOVA) with
Bonferroni corrected t-tests was used to assess annual
days off work. All analyses were carried out using
STATA 10.1 (StataCorp 2007. Stata Statistical Software:
Release 10. College Station, TX: StataCorp LP).
Results
Physician-recorded patient data (PRFs) were available for
3572 patients, of whom 2171 (60.8%) completed a
patient-recorded questionnaire (PSC). T25FW data were
available for 184 patients (5.1%). Table 1 details the
demographics and disease characteristics for the total pa-
tient population (N = 3572).
Burden of WMPs in MS
Of the patients who provided information about the
presence and severity of WMPs (N = 2111), 1342 (64%)
reported no WMPs, 271 (13%) reported having mild
WMPs, 314 (15%) reported having moderate WMPs, and
184 (9%) indicated that they considered their WMPs to
be severe.
‘Bothersomeness’ of WMPs in MS
Among the patients who responded regarding their most
bothersome symptom (N = 683), 291(43%) patients con-
sidered this to be their WMPs. Of these 291 patients, 78
(27%) reported having mild WMPs, 122 (42%) reported
having moderate WMPs and 91 (31%) reported having
severe WMPs.
Requirement for care and mobility assistance
Among patients with both T25FW and caregiver require-
ment data (N = 183), ordered logistic regression analysisshowed a significant association between T25FW and
overall (professional and non-professional) caregiver re-
quirement (P < 0.0001) with patients with longer T25FW
times being more likely to require both formal and infor-
mal care (Figure 1).
Among patients who provided information about the
presence and severity of WMPs and healthcare resource
utilization (N = 2063), need for mobility aids also rose with
increased WMPs. The proportion of patients requiring a
walking frame increased from 3% for patients with no
WMPs to 6% (mild), 13% (moderate) and 24% (severe)
(P < 0.0001) (P < 0.0001). Among patients with no or only
mild WMPs, 13% required a cane or walking stick com-
pared with 39% of patients with moderate WMPs and 28%
of patients with severe WMPs (P < 0.0001). However 58%
of patients with severe WMPs require the use of a wheel-
chair compared with only 6% of those with no WMPs, 7%
with mild WMPs and 11% with moderate WMPs (P <
0.0001).Healthcare resource utilization
Among patients with both T25FW and healthcare re-
source utilization data (N = 184), statistically significant
increases in overall resource utilization among patients
were observed as timed-walk duration increased (Table 2).
Specifically, primary care consultations (p = 0.0044),
urologist visits (P = 0.006), time spent with occupational
therapists P = 0.0104, and the number of long-term non-
disease modifying drugs used increased significantly with
increased duration of the T25FW (P = 0.0001). No signifi-
cant differences were observed in the frequency and length
of hospital stay with increased duration of the T25FW.
The pattern for ER visits in the previous 12 months was
more complex. There was no difference in the number of
annual visit for patients in the lowest and highest T25FW
time groups (0.32 and 0.31 visits in the <11and >21 sec-
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Figure 1 Relationship between increased T25FW times and the need for patient caregiver assistance.
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group (0.15 visits).
Among patients who provided information about the
presence and severity of WMPs and healthcare resource
utilization, the presence of patient-reported WMPs cor-
related significantly with almost all health care resource
use parameters measured as part of this study including
mean annual ER visits (P = 0.0014), primary care consul-
tations (P < 0.0001), neurologist (P = 0.0045), internist
(P = 0.0006) and urologist (P < 0.0001) consultations, as
well as time spent with other health care providers,
the number of long-term non-disease modifying drugs
(P < 0.0001), and hospitalizations in the last 12 months
(P < 0.0001) (Table 2).
Ability to work
Among patients with T25FW and employment data
(N = 184), the number of patients working full time
decreased as T25FW time increased (p < 0.0001 across
the three groups; Table 3). The greatest decrease com-
pared with those in the <11 second category was among
those in the 11–21 second category 56.0% vs 12.7%,
respectively). The proportion of patients working part
time increased compared to the <11 second group (12%)
to approximately 3-fold in the 11–21 second category
(38.2%), and approximately 2-fold in the >21 seconds
category (19.2%) (p = 0.0015 across the three groups). A
greater proportion of patients reported a reduction in
their weekly work-hours as the duration of the T25FW
increased although the differences across the three
groups did not reach statistical significance (P = 0.0527).
Of the patients who provided information about the
presence and severity of WMPs and work activity, statis-
tically significant reductions in all measures of work ac-
tivity (full-time, part-time, annual days off work, reducedweekly work-hours, and stopping work) were reported
with the presence and increasing severity of WMPs
(Table 3).
Representativeness of the cohorts
Additional analyses were undertaken in order to deter-
mine whether there were any significant differences be-
tween the various cohorts in that were compared in the
analyses described above (Table 4).
The distribution of patients by gender and employ-
ment type between the cohort who completed a PSC and
those who did not was similar although there were pro-
portionately more females and manual workers in the
cohort who did not complete a PSC. The cohort who
did complete a PSC tended towards slightly higher
physician-reported mean scores across a range of mobil-
ity problems collected in the PRF although there was no
difference in term so the most recent mean EDSS score.
Few differences were noted between the cohort of
patients for whom a T25FW score was available and
those without such a score. The only significant differ-
ence was a higher physician-reported mean muscle atro-
phy score in the cohort with a T25FW score.
Discussion
The results of the cross-sectional, patient record-based
study presented here demonstrated that a significant
proportion of patients with MS experience walking and
mobility problems (WMPs) and the majority of patients
consider them to be their most bothersome symptom.
These data are consistent with those reported by Heesen
and co-workers [26] who found that among a cohort of
166 patients with MS, walking was regarded by patients
as the most valuable function, followed by visual func-
tioning and cognition. These data add further weight to
Table 2 Summary of healthcare resource utilization by T25FW category and patient self-reported WMP presence and
severity
Resource (mean [SD]
use in last 12 months)
Patient-self-reported presence and severity of WMPs T25FW (seconds)
None Mild Moderate Severe P-value no
WMPs vs any
WMPs
<10.99 11–20.99 >21 P-value
across
groups
ER visits 0.23 [0.61] 0.24 [0.63] 0.21 [0.68] 0.45 [1.09] 0.014 0.32 [0.53] 0.15 [0.41] 0.31 [0.59] 0.1592
Physician visits
Responding neurologist 3.23 [2.55] 3.93 [4.51] 3.76 [3.58] 4.13 [6.39] 0.003 5.07 [9.76] 3.68 [3.86] 3.60 [2.36] 0.3694
Primary care provider 1.71 [2.62] 2.01 [3.97] 1.86 [3.11] 2.86 [4.23] < 0.0001 1.37 [2.20] 2.84 [4.33] 3.13 [3.12] 0.0044
Other neurologist 0.59 [1.09] 0.51 [1.11] 0.81 [1.91] 0.80 [1.38] 0.0045 0.80 [1.14] 0.61 [0.96] 0.54 [0.94] 0.3341
MS specialist 0.30 [1.09] 0.26 [0.75] 0.36 [1.24] 0.52 [1.59] 0.0633 0.75 [1.18] 0.47 [0.95] 0.42 [1.00] 0.1718
MS nurse 0.36 [2.05] 0.42 [1.99] 0.45 [1.91] 0.42 [1.83] 0.8858 0.33 [0.74] 0.47 [1.26] 0.35 [1.12] 0.7124
Internist 0.06 [0.40] 0.09 [0.52] 0.08 [0.42] 0.23 [1.11] 0.0006 0.27 [0.98] 0.11 [0.67] 0.10 [0.50] 0.3628
ER physician 0.03 [0.36] 0.29 [3.11] 0.05 [0.58] 0.05 [0.34] 0.0116 0.01 [0.12] 0.02 [0.13] 0.00 [0.00] 0.6577
Physiotherapist 1.97 [10.45] 4.74 [15.54] 6.88 [18.35] 9.89 25.52] < 0.0001 3.63 [14.57] 10.26 [31.77] 6.04 [15.82] 0.22
Ophthalmologist 0.19 [0.58] 0.21 [0.82] 0.10 [0.42] 0.15 [0.57] 0.0579 0.23 [0.65] 0.21 [0.65] 0.10 [0.36] 0.4269
Urologist 0.12 [0.47] 0.18 [0.85] 0.30 [0.86] 0.57 [1.37] < 0.0001 0.12 [0.54] 0.18 [0.43] 0.50 [1.00] 0.006
Gastroenterologist 0.01 [0.13] 0.03 [0.49] 0.02 [0.15] 0.03 [0.19] 0.3492 0.01 [0.12] 0.04 [0.19] 0.08 [0.33] 0.2716
Psychiatrist 0.19 [1.65] 0.28 [1.70] 0.28 [1.27] 0.69 [4.05] 0.0595 0.35 [1.79] 0.25 [0.63] 0.42 [1.23] 0.7918
Other physician 0.04 [0.31] 0.28 [3.19] 0.10 [0.51] 0.17 [0.70] 0.0222 0.05 [0.28] 0.04 [0.19] 0.08 [0.44] 0.7806
Occupational therapist 0.01 [0.22] 0.06 [0.51] 0.20 [1.09] 1.11 [2.47] < 0.0001 0.09 [0.66] 0.00 [0.00] 0.77 [2.11] 0.0104
Hospital visits due to MS in
last 12 months
0.93 [1.26] 1.11 [1.55] 1.17 [1.64] 1.76 [2.72] < 0.0001 1.04 [0.81] 0.93 [1.28] 0.70 [0.74] 0.1561
Number of long-term non-DMDs 0.54 [0.78] 0.82 [0.92] 1.23 [1.12] 1.72 [1.18] <0.0001 0.57 [0.76] 1.21 [0.86] 1.12 [1.02] 0.0001
DMDs, disease-modifying drugs; ER, Emergency Room; MS, multiple sclerosis; SD, standard deviation; T25FW, timed 25-foot walk test; WMPs, walking and mobility
problems.
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symptom from the patient’s perspective and therefore as
a target for therapeutic intervention.
The results presented here also demonstrate a clear,
independent, and strong directional relationship between
the severity of WMPs (both from a subjective symptom
assessment and from objective T25FW test results) and
healthcare resource utilization (including the requirement
for both professional and non-professional care), and as-
sistance with walking. These data highlight the economicTable 3 Summary of work activity by T25FW category and pa
Work activity Patient-self-reported presen
None Mild Moderate
Full time, % respondents 46.55 34.70 19.03
Part time, % respondents 15.77 22.76 17.42
Reduced weekly working hours due to MS,
% respondents
11.54 25.68 22.37
Stopped work due to MS, % respondents 7.16 11.67 28.95







[106.69]burden imposed by WMPs on MS patients. As such, these
patients and/or healthcare systems will need to meet the
costs of health and social care provision to address their
daily needs. These results are consistent with a recent
European survey in which patients were stratified based
on their EDSS score [8]. The EDSS relies heavily on
walking ability as a component of overall disease-related
disability, and Kobelt and co-workers reported that
requirements for, and costs associated with, healthcare re-
source utilization, the need for informal care, and home-tient self-reported WMP presence and severity









9.34 <0.0001 56.00 12.73 38.46 <0.0001
8.24 0.0006 12.00 38.18 19.23 0.0015
21.59 <0.0001 22.00 32.50 25.58 0.527










Table 4 Representativeness of the PSC vs non-PSC and the T25FW and non-T25FW cohorts
Characteristic PSC Non-PSC P-value T25FW Non-25FW P-value
Gender, % N = 2169 N = 1397 0.0384 N = 184 N = 3382 0.8527
Male 38 34 36 37
Female 62 66 64 63
Employment type, % N = 1048 N = 593 0.0004 N = 98 N = 1543 0.2362
Manual skilled 25 30 22 27
Manual unskilled 15 19 12 17
Non-Manual 60 51 66 56
Time since diagnosis,
N N = 1941 N = 1156 0.0330 N = 176 N = 2921 0.6199
Mean years 6.2 5.7 5.8 6.0
Mobility problems (PRF-reported), mean N = 2124 N = 1381 N = 181 N = 3324
Paraesis 0.90 0.86 0.2499 0.90 0.88 0.5122
Plegia 0.25 0.26 0.9536 0.25 0.25 0.9063
Spasticity 0.59 0.48 0.0001 0.61 0.54 0.1503
Muscle atrophy 0.15 0.09 0.0001 0.03 0.14 0.0085
Spasms/cramps 0.29 0.22 0.0001 0.30 0.26 0.2680
Footdrop 0.15 0.08 0.0001 0.13 0.12 0.4241
Ataxia 0.58 0.53 0.1016 0.54 0.56 0.9508
Dystonia 0.04 0.02 0.0091 0.04 0.03 0.4537
Fatigue 0.84 0.77 0.0219 0.85 0.81 0.3428
Most recent EDSS score
N N = 1845 N = 1211 0.5724 N = 151 N = 2905 0.4510
Mean 3.24 3.20 3.1 3.2
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EDSS-assessed disability.
Work activity was also markedly impacted by the pres-
ence of WMPs. Even patients who reported mild WMPs
experienced some impairment in terms of work activity
suggesting a societal need for addressing this functional
impairment early in the disease course. These data are
consistent with those reported by Kobelt and co-workers
([8] and also Salter and co-workers [11] and are of par-
ticular relevance given that patients are often diagnosed
with the disease during early adulthood. In the European
survey reported by Kobelt and co-workers (described
above), work capacity (proportion of patients ≤65 years
working) declined as EDSS-assessed disability increased.
Salter and co-workers [11] used the NARCOMS mobility
performance sub-scale to examine the impact of reduced
mobility on activities of daily living and socioeconomic
status. As observed in the current study, decreasing mo-
bility was associated with increased unemployment and
decreased full-tome work status, even at low levels of
reduced mobility. Such early and on-going impact on
ability to work has the potential to impact on a patient’s
long-term quality of life and psychological well-being.The DSP represents a large cross-sectional study of
patients with MS of all severities and the physicians
treating them. The data generated provides an insight
into the problems associated with MS and the social and
economic burden presented by this debilitating disease.
Limitations specific to the MS DSP include the sample
size in relation to the T25FW with data available for 184
patients (5.1% of the total study population). However
the T25FW is a measure which, while used in clinical
studies, is not routinely used in clinical practice. In the
DSP sample, the 184 patients for whom T25FW was
available were provided by 62 of the 340 physicians who
participated; 278 physicians did not provide any T25FW
data. Physicians were not asked to conduct this evalu-
ation specifically for the purposes of this study but to
provide the data where previously available in the med-
ical record or where the test had been conducted as part
the routine consultation process. An additional analysis
did not identify any consistent differences between the
cohort of patients for whom T25FW data were available
and those without such data. This observation suggests
that the subset of patients for whom T25FW data were
available was representative of the whole cohort in terms
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their physicians. Some differences were noted between
the cohort of patients who completed a PSC and those
who did not. For example, in the cohort of patients who
did complete a PSC the proportion of females was
slightly lower and the proportion engaged in manual
work was somewhat higher. In addition, physician rat-
ings of mobility problems were generally higher among
those who completed a PSC. This latter observation sug-
gests that the cohort with PSC data may have had more
severe mobility issues although the actual numerical dif-
ferences in the mean scores were small. The population
studied here represents the population of MS patients
consulting a neurologist and so may exclude patients not
directly or routinely under neurologist care at the time
of the study. Thus the population represented here are
patients more likely to be receiving a degree of routine
specialist MS care.Conclusion
In conclusion, while the results presented should be con-
sidered within the context of the limitations regarding
their generalizability to the whole population of patients
with MS, they do provide a valuable insight into the po-
tential for significant impact of walking and mobility
issues on all aspects of a patients life. Consequently, the
results also highlight the need for clinicians to question
patients about their walking and mobility problems at
the first encounter and to monitor the patient for any
changes at regular intervals (at least at each clinic visit).
Finally, this Europe-based survey of the burden of mobil-
ity problems among patients with MS demonstrated that
these patients could benefit from therapies that specific-
ally address functional impairment of walking and mobil-
ity. Therapies that specifically improve WMPs including
walking speed as measured, for example, using the
T25FW, could have a positive socio-economic impact by
potentially reducing healthcare resource utilization, the
requirement for both formal and informal care, and
mobility aids, as well as improving or preserving work
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